About Norgine
Norgine is a company based in Amsterdam (Netherlands) founded in 1906 was acquired by Goldman Sachs in May 2022. Norgine has completed 3 acquisitions, including Azanta, Merus Labs and Theravia. Norgine operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
- Headquarter Amsterdam, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Investments & Acquisitions
Azanta
& 2 more
-
Acquired by
Goldman Sachs
(May 26, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Norgine
Unlock access to complete
Software Development Team
42 people
Leadership Team
28 people
Human Resources and Administration
12 people
Sales and Marketing
12 people
Product Management Team
10 people
Senior Team
9 people
Legal and Compliance
7 people
Global Team
6 people
Unlock access to complete
Funding Insights of Norgine
Detailed funding history for Norgine
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Norgine
Norgine has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Goldman Sachs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked |
Investor details for Norgine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Norgine
Norgine has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Azanta, Merus Labs and Theravia.
Investment portfolio details for Norgine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceuticals for women's health, cancer, infectious and cardiovascular disease.
|
Locked | Locked | 2009 | Locked | |
|
Medicines for orphan oncology and women's health devices are developed.
|
Locked | Locked | 1994 | Locked | |
|
Therapies for rare and neglected diseases are developed and promoted.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Norgine
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Norgine
Detailed financials for Norgine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Norgine Comparisons
Peer comparison for Norgine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Norgine
Norgine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
Detailed competitors of Norgine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Norgine
Complete news archive for Norgine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Norgine
Norgine was founded in 1906.
Norgine is headquartered in Amsterdam, Netherlands.
Norgine was founded in 1906 and is headquartered in Amsterdam, Netherlands. Operations in the pharmaceutical sector are centered on the development and marketing of therapeutic products, with primary emphasis on gastrointestinal diseases and additional involvement in hepatology and critical care. A portfolio of 9 products generated EUR 300M in revenue during 2015. Seven pipeline candidates are under development, including five for gastroenterology and two for critical care.
Norgine's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Norgine has made 3 acquisitions, including Azanta, Merus Labs, and Theravia.
Norgine has 1 investor. Key investors include Goldman Sachs.